180 related articles for article (PubMed ID: 37774055)
61. A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases.
Chun YJ; Kim SG; Lee KW; Cho SH; Kim TW; Baek JY; Park YS; Hong S; Chu CW; Beom SH; Jung M; Shin SJ; Ahn JB
Clin Colorectal Cancer; 2020 Sep; 19(3):e140-e150. PubMed ID: 32402681
[TBL] [Abstract][Full Text] [Related]
62. Treatment strategies to resectable metachronous colorectal liver metastases after adjuvant oxaliplatin-based chemotherapy for primary colorectal cancer.
Julio C; Benoist S; Allard MA; Navarro F; Pessaux P; Sa Cunha A; Brouquet A;
J Surg Oncol; 2022 Aug; 126(2):330-338. PubMed ID: 35397122
[TBL] [Abstract][Full Text] [Related]
63. Early Recurrence After Hepatectomy for Colorectal Liver Metastases: What Optimal Definition and What Predictive Factors?
Imai K; Allard MA; Benitez CC; Vibert E; Sa Cunha A; Cherqui D; Castaing D; Bismuth H; Baba H; Adam R
Oncologist; 2016 Jul; 21(7):887-94. PubMed ID: 27125753
[TBL] [Abstract][Full Text] [Related]
64. Phase II trial of neoadjuvant chemotherapy with S-1 and oxaliplatin plus bevacizumab for colorectal liver metastasis (N-SOG 05 trial).
Mukai T; Uehara K; Goto H; Hiramatsu K; Kobayashi S; Sakamoto E; Maeda A; Takeuchi E; Okada Y; Ebata T; Nagino M;
Jpn J Clin Oncol; 2017 Jul; 47(7):597-603. PubMed ID: 28398493
[TBL] [Abstract][Full Text] [Related]
65. The prognosis of liver resection for patients with four or more colorectal liver metastases has not improved in the era of modern chemotherapy.
Hokuto D; Nomi T; Yamato I; Yasuda S; Obara S; Yoshikawa T; Kawaguchi C; Yamada T; Kanehiro H; Nakajima Y
J Surg Oncol; 2016 Dec; 114(8):959-965. PubMed ID: 27683191
[TBL] [Abstract][Full Text] [Related]
66. Clinical efficacy of liver resection after downsizing systemic chemotherapy for initially unresectable liver metastases.
Kawamura J; Yazawa T; Sumida K; Kida Y; Ogawa R; Tani M; Kawasoe J; Yamamoto M; Harada H; Yamamoto H; Zaima M
World J Surg Oncol; 2016 Feb; 14():56. PubMed ID: 26911142
[TBL] [Abstract][Full Text] [Related]
67. Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases.
Liu JH; Hsieh YY; Chen WS; Hsu YN; Chau GY; Teng HW; King KL; Lin TC; Tzeng CH; Lin JK
Int J Colorectal Dis; 2010 Oct; 25(10):1243-9. PubMed ID: 20574727
[TBL] [Abstract][Full Text] [Related]
68. Detailed liver-specific imaging prior to pre-operative chemotherapy for colorectal liver metastases reduces intra-hepatic recurrence and the need for a repeat hepatectomy.
Knowles B; Welsh FK; Chandrakumaran K; John TG; Rees M
HPB (Oxford); 2012 May; 14(5):298-309. PubMed ID: 22487067
[TBL] [Abstract][Full Text] [Related]
69. Effect of Neoadjuvant Chemotherapy in Patients with Colorectal Cancer Liver Metastases.
Sui K; Okabayashi T; Iwata J; Morita SM; Matsumoto T; Inada R; Iiyama T; Shimada Y; Kobayashi M
Surg Technol Int; 2019 May; 34():208-214. PubMed ID: 31037714
[TBL] [Abstract][Full Text] [Related]
70. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases.
Andreou A; Kopetz S; Maru DM; Chen SS; Zimmitti G; Brouquet A; Shindoh J; Curley SA; Garrett C; Overman MJ; Aloia TA; Vauthey JN
Ann Surg; 2012 Oct; 256(4):642-50. PubMed ID: 22968062
[TBL] [Abstract][Full Text] [Related]
71. The clinical relevance of the Fong and the Nordlinger scores in the era of effective neoadjuvant chemotherapy for colorectal liver metastasis.
Schreckenbach T; Malkomes P; Bechstein WO; Woeste G; Schnitzbauer AA; Ulrich F
Surg Today; 2015 Dec; 45(12):1527-34. PubMed ID: 25563588
[TBL] [Abstract][Full Text] [Related]
72. A survival analysis of the liver-first reversed management of advanced simultaneous colorectal liver metastases: a LiverMetSurvey-based study.
Andres A; Toso C; Adam R; Barroso E; Hubert C; Capussotti L; Gerstel E; Roth A; Majno PE; Mentha G
Ann Surg; 2012 Nov; 256(5):772-8; discussion 778-9. PubMed ID: 23095621
[TBL] [Abstract][Full Text] [Related]
73. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
[TBL] [Abstract][Full Text] [Related]
74. Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases.
Pietrantonio F; Di Bartolomeo M; Cotsoglou C; Mennitto A; Berenato R; Morano F; Coppa J; Perrone F; Iacovelli R; Milione M; Alessi A; Vaiani M; Bossi I; Ricchini F; Scotti M; Caporale M; Bajetta E; de Braud F; Mazzaferro V
Clin Colorectal Cancer; 2017 Sep; 16(3):e191-e198. PubMed ID: 27979717
[TBL] [Abstract][Full Text] [Related]
75. Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy - a randomized phase II study -- SULTAN UCGI 30/PRODIGE 53 (NCT03164655)- study protocol.
Boilève A; Maillard A; Wagner M; Dromain C; Laurent C; Dupont Bierre E; Le Sourd S; Audemar F; Ulusakarya A; Guerin-Meyer V; Smisth D; Pezzella V; De Baere T; Goere D; Gelli M; Taieb J; Boige V
BMC Cancer; 2020 Jan; 20(1):74. PubMed ID: 32000724
[TBL] [Abstract][Full Text] [Related]
76. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer.
Turan N; Benekli M; Koca D; Ustaalioglu BO; Dane F; Ozdemir N; Ulas A; Oztop I; Gumus M; Ozturk MA; Berk V; Kucukoner M; Uner A; Balakan O; Helvaci K; Ozkan S; Yilmaz U; Buyukberber S;
Oncology; 2013; 84(1):14-21. PubMed ID: 23076023
[TBL] [Abstract][Full Text] [Related]
77. Survival benefit of neoadjuvant chemotherapy and surgery versus surgery first for resectable colorectal liver metastases: a cohort study.
Behrenbruch C; Prabhakaran S; Udayasiri D; Hollande F; Michael M; Hayes I; Heriot A; Knowles B; Thomson B
ANZ J Surg; 2021 Jun; 91(6):1196-1202. PubMed ID: 33543551
[TBL] [Abstract][Full Text] [Related]
78. Pathological response of colorectal liver metastases treated after induction treatment.
Ben Slama S; Bacha D; Sassi A; Khadhar A; Bayar R; Bouraoui S; Lahmar A
Tunis Med; 2017 Oct; 95(10):854-858. PubMed ID: 29873054
[TBL] [Abstract][Full Text] [Related]
79. Neo-adjuvant Chemotherapy-Induced Neutropenia Is Associated with Histological Responses and Outcomes after the Resection of Colorectal Liver Metastases.
Chen Q; Wu C; Zhao H; Wu J; Zhao J; Bi X; Li Z; Huang Z; Zhang Y; Zhou J; Cai J
J Gastrointest Surg; 2020 Mar; 24(3):659-670. PubMed ID: 30937711
[TBL] [Abstract][Full Text] [Related]
80. Impact of autotransfusion on recurrence of colorectal cancer liver metastasis: Long-term follow-up of patients undergoing curative intent hepatectomy.
Wehrle CJ; Perlmutter B; Hong H; Chang J; Stackhouse KA; Naples R; Shanaz Hossain M; Joyce D; Simon R; Kim J; Naffouje SA; Aucejo F; Kwon DCH; Walsh RM; Augustin T
J Surg Oncol; 2024 Mar; 129(4):793-801. PubMed ID: 38151831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
